Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Diabetes R & D Pipeline: Cell and Stem Cell Therapies

Published by: BioPolaris

Published: Sep. 1, 2009 - 32 Pages


Table of Contents


1. Islet Cell Therapies

1.1. Allotransplantation

1.2. Xenotransplantation

1.2.1. Genetically Engineered Pigs
1.3. Genetically engineered islet cells
1.4. Isolation of Human Pancreatic Islet Cells

1.5. Purification and Culture of Human Islet Cells

1.6. Expansion of Islet Cells

1.7. Encapsulation of Islet Cells

1.8. Delivery of Islet Cells

1.9. Quality of Islet Cells and Transportation Issues

1.10. Results of Islet Cell Transplantation for the Treatment of Diabetes

1.11. Complications of Islet Cell Therapy

1.12. Regulations

2. Stem Cell Therapies for the Treatment of Diabetes

2.1. Adult Stem Cells

2.1.1. Extraction of Adult Stem Cells
2.1.2. Identification and Isolation of Adult Stem Cells

2.1.3. Expansion of Adult Stem Cells

2.1.4. Encapsulation of Adult Stem Cells

2.1.5. Reprogramming and Differentiation of Adult Stem Cells

2.2. Human Embryonic Stem Cells (hESCs) or Pluripotent Stem Cells
2.2.1. Differentiation of Pluripotent Stem Cells to Insulin Producing Cells
2.3. Delivery of Stem Cells for the Treatment of Diabetes
2.4. Results of Clinical Trials

2.5. Guidelines for Stem Cell Research

2.6. Perspectives of Stem Cell Therapies for the Treatment of Diabetes

2.7. The US National Institutes of Health (NIH) Funding of Stem Cell Research for the Treatment of Diabetes

3. Other Cell Therapies

3.1. Adult Mesenchymal Stem Cells (MSCs)

3.1.1. Mechanism of Action.
3.1.2. Results of Adult Mesenchimal Stem Cell Therapy

3.2. Autologous Nonmyeloablative Hematopoetic Stem Cells
3.2.1. Mechanism of Action
3.2.2. Results of Autologous Nonmyeloablative Hematopoetic Stem Cell Therapy

3.3. Autologous Adipose-Derived Stem Cells
3.3.1. Mechanism of Action
3.3.2. Results of Autologous Adipose-Derived Stem Cell Therapy

4. Product Profiles

Each product profile contains information related to indication, development status, development stage, product characteristics, mechanism of action, results of clinical trials (efficacy and safety),origin, development company, co-development company (if applicable), date of publishing and comments (including technology, agreements etc.).

5. Company Profiles

This section includes each company profile and, when available, information regarding its market capital and number of employees.

6. Venture Capital Companies and Institutional Investors

In the past, at least seven venture capital companies were investing in private biopharmaceutical and pharmaceutical companies developing cell and stem cell therapies for the treatment of diabetes.

The major institutional investors and their percentage of shares are listed in Table 4. Notably,Barclays Global Investors UK Holdings, Ltd. (UK) has investment in almost all listed public USA companies involved in cell and stem cell research and development for the treatment of diabetes,holding between 3% to 5.5% of their share.

Tables

Table 1. Diabetes R & D Pipeline: Cell and Stem Cell Therapies

Table 2. Encapsulation and Delivery of Cell and Stem Cell Products for the Treatment of Diabetes

Table 3. Companies and Investors

Abstract

This report addresses the recent advances in research and development of pancreatic islet cell and stem cell therapies for the treatment diabetes, primarily of type 1 diabetes. The report features 10 cell and stem cell products which are undergoing development  for the treatment of diabetes, particularly type1 diabetes.

Management of type 1 diabetes is taxing, both to patients and society, with cost of over $100 billion annually in the USA alone. Despite the widespread use of glucose monitoring and new insulin formulations, many patients with type 1 diabetes still develop devastating secondary complications, including diabetic nephropathy, neuropathy, retinopathy and diabetic ulcers.

Pancreatic islet cell transplantation and stem cell therapies have potential to restore glucose control in patients with diabetes without risk of serious hypoglycemic adverse effects associated with insulin therapy.

Cell therapies for the treatment of patients with diabetes included in the report are:
    1. islet cell therapies
    2. stem cell therapies
    3. other cell therapies
The report contains six sections.
    1. Islet Cell Therapies
    2. Stem Cell Therapies for the Treatment of Diabetes
    3. Other Cell Therapies
    4. Product Profiles
    5. Company Profiles
    6. Venture Capital Companies and Institutional Investors


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009